HER2-NEGATIVE BREAST CANCER
Clinical trials for HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising cancer drug trial halted early
Disease control TerminatedThis study tested a new drug called BLU-222 in people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if it could shrink tumors. The trial was stopped early, so results are limited.
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated May 26, 2026 04:23 UTC
-
Radioactive cancer drug trial halted early
Disease control TerminatedThis study tested a radioactive drug called [225Ac]-FPI-1434 in people with advanced solid tumours that had not responded to standard treatments. The goal was to find a safe dose and see if it could shrink tumours. The trial was stopped early, so results are limited. Participants…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 26, 2026 04:18 UTC
-
Promising combo trial for aggressive breast cancer halted early
Disease control TerminatedThis study tested a new drug called azenosertib combined with two standard cancer drugs (carboplatin and pembrolizumab) in people with metastatic triple-negative breast cancer. The goal was to find the safest dose and see if the combination could shrink tumors. Only 7 people took…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Filipa Lynce, MD • Aim: Disease control
Last updated May 26, 2026 03:54 UTC
-
Cancer drug study halted early: what happened?
Disease control TerminatedThis study tested an experimental drug called VLS-101 in people with advanced solid tumors, including breast, lung, stomach, pancreatic, and ovarian cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. However, the study…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
Early trial of targeted combo for rare breast cancer subtype ends early
Disease control TerminatedThis early-phase study tested a new drug (infigratinib) combined with tamoxifen for people with a specific advanced breast cancer that is hormone receptor-positive, HER2-negative, and has changes in the FGFR gene. The main goal was to find a safe dose by monitoring side effects. …
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Jennifer Lee Caswell-Jin • Aim: Disease control
Last updated May 06, 2026 16:03 UTC